Broadly protective vaccine candidates for Group A Streptococcus (GAS) to prevent common and serious GAS infections
Official title: Discovery of Group A Streptococcus antigens for development of broadly effective vaccine candidates to prevent non-invasive and invasive disease and emergence of antimicrobial resistance
Funded at Immport Therapeutics, INC. · NIH-11316419 · Data updated 2026-11-12
Researchers are developing a GAS vaccine aimed at protecting people of all ages from common and severe GAS infections and reducing immune-related complications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immport Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | August 26, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $300,000 |
| NIH project number | 1R43AI192098-01A1 |
| Project ID | NIH-11316419 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals across a wide age range (children 0-11 and adults 21+ years) who are at risk of GAS infections and may benefit from future vaccination.
✕Less likely to help
People with conditions not related to GAS infections or those who would not be recipients of a GAS vaccine may not directly benefit.
What this research studies
This project focuses on identifying GAS antigens that could form a vaccine capable of preventing both non-invasive illnesses like strep throat and skin infections, as well as invasive GAS diseases. The work includes studying how the immune system recognizes GAS and which antigens provoke a protective antibody response. By mapping these targets, the team hopes to create broadly effective vaccine candidates suitable for people from early childhood to older adulthood. The grant supports early-stage development and testing to move promising vaccines toward clinical evaluation.
Why it matters
Potential benefit: If successful, the vaccine could reduce GAS infections and prevent serious complications such as rheumatic fever and invasive disease, improving public health globally.
How similar studies have gone: Prior work suggests that vaccine approaches against GAS antigens can elicit protective antibody responses, but broadly effective vaccines are still under development.
Where this research is happening
-
Immport Therapeutics, INC.
Irvine, United States Active
Researchers
- Principal investigator: Campo, Joseph J. — Immport Therapeutics, INC.
- Study coordinator: Campo, Joseph J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.